loading...| Preferred Name |
Porcupine Inhibitor ETC-1922159 |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123830 |
| CAS_Registry |
1638250-96-0 |
| code |
C123830 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 |
| Contributing_Source |
CTRP GDC FDA |
| DEFINITION |
An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, ETC-1922159 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational palmitoylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers. |
| Display_Name |
Porcupine Inhibitor ETC-1922159 |
| FDA_UNII_Code |
5L854240DQ |
| FULL_SYN |
PORCN Inhibitor ETC-1922159 ETC-159 ETC-1922159 Porcupine Inhibitor ETC-1922159 |
| Has_Target | |
| Is_Value_For_GDC_Property | |
| label |
Porcupine Inhibitor ETC-1922159 |
| Maps_To |
Porcupine Inhibitor ETC-1922159 |
| NCI_Drug_Dictionary_ID |
775936 |
| NCI_META_CUI |
CL498223 |
| PDQ_Closed_Trial_Search_ID |
775936 |
| PDQ_Open_Trial_Search_ID |
775936 |
| Preferred_Name |
Porcupine Inhibitor ETC-1922159 |
| prefixIRI |
Thesaurus:C123830 |
| prefLabel |
Porcupine Inhibitor ETC-1922159 |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| There are currently no mappings for this class. | |||